Search

Innate Pharma SA

Затворен

1.854 3

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.8439999999999999

Максимум

1.8559999999999999

Ключови измерители

By Trading Economics

Приходи

3.4M

-21M

Продажби

531K

4.9M

Марж на печалбата

-439.177

Служители

174

EBITDA

-2M

-25M

Препоръки

By TipRanks

Препоръки

Неутрален

12-месечна прогноза

+20.41% upside

Пазарни показатели

By TradingEconomics

Пазарна капитализация

13M

170M

Предишно отваряне

-1.15

Предишно затваряне

1.854

Техническа оценка

By Trading Central

Увереност

Weak Bullish Evidence

Innate Pharma SA Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

24.10.2025 г., 18:41 ч. UTC

Печалби

Procter & Gamble to Focus on Innovation, Not Discounts, to Attract Wary Shoppers - 2nd Update

24.10.2025 г., 18:31 ч. UTC

Печалби

Correction to Procter & Gamble to Focus on Innovation

24.10.2025 г., 16:25 ч. UTC

Значими двигатели на пазара

Obook Shares Rise, Company Secures New Money Transmitter Licenses

24.10.2025 г., 21:24 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

24.10.2025 г., 21:24 ч. UTC

Пазарно говорене

Moody's Sees France With Increased Risk of Political Dysfunction -- Market Talk

24.10.2025 г., 21:07 ч. UTC

Печалби

The Score: Netflix, Amazon.com, Six Flags and More Stocks That Defined the Week -- WSJ

24.10.2025 г., 20:58 ч. UTC

Печалби

S&P 500 Climbs to New Record on Strong Earnings -- WSJ

24.10.2025 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

24.10.2025 г., 20:40 ч. UTC

Печалби

Intel Expects Chip Shortages on Better PC Demand. Here's Why AMD Is Winning Too. -- Barrons.com

24.10.2025 г., 20:24 ч. UTC

Печалби

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24.10.2025 г., 20:23 ч. UTC

Печалби

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24.10.2025 г., 20:13 ч. UTC

Печалби

These Stocks Moved the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24.10.2025 г., 20:07 ч. UTC

Пазарно говорене

Different-Cell Imputation Rose Proportionally in September CPI -- Market Talk

24.10.2025 г., 19:40 ч. UTC

Пазарно говорене

Treasury Yields Mixed, Dollar Stronger Ahead of Fed Week -- Market Talk

24.10.2025 г., 19:35 ч. UTC

Пазарно говорене

Oil Rally on U.S. Russia Sanctions Loses Steam -- Market Talk

24.10.2025 г., 19:33 ч. UTC

Печалби

IBM and Google Are Also Making Moves in Quantum. Don't Count Out the Bigger Players. -- Barrons.com

24.10.2025 г., 19:29 ч. UTC

Пазарно говорене

U.S. Natural Gas Ends Week Higher on Weather Outlook -- Market Talk

24.10.2025 г., 18:52 ч. UTC

Печалби

Correction to GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24.10.2025 г., 18:41 ч. UTC

Печалби

GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24.10.2025 г., 18:03 ч. UTC

Печалби

Beyond Meat Stock Is on a Wild Ride. Why a Meme Rally Looks Undercooked. -- Barrons.com

24.10.2025 г., 18:02 ч. UTC

Печалби

Progressive Stock Got Hit After Earnings. It's Time to Buy One of America's Great Companies. -- Barrons.com

24.10.2025 г., 18:00 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Rises By Two to 420 -- Market Talk

24.10.2025 г., 16:57 ч. UTC

Печалби

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

24.10.2025 г., 16:54 ч. UTC

Пазарно говорене

End to Canada-U.S. Trade Talks Not Seen Shifting Nearterm Outlook -- Market Talk

24.10.2025 г., 16:44 ч. UTC

Пазарно говорене
Печалби

Amazon Retail Looks Strong as Consumer Sentiment Improves -- Market Talk

24.10.2025 г., 16:39 ч. UTC

Пазарно говорене
Печалби

Amazon Sentiment Around AWS Seen as Improving in 3Q -- Market Talk

24.10.2025 г., 16:33 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24.10.2025 г., 16:23 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24.10.2025 г., 16:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

24.10.2025 г., 16:07 ч. UTC

Печалби

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

Innate Pharma SA Прогноза

Ценова цел

By TipRanks

20.41% нагоре

12-месечна прогноза

Среден 2.228 EUR  20.41%

Висок 2.23 EUR

Нисък 2.23 EUR

Според 1 анализатори от Wall Street, предложили 12-месечна ценова цел за Innate Pharma SA през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

1 ratings

0

Купи

1

Задържане

0

Продай

Техническа оценка

By Trading Central

1.91 / 2.1Подкрепа & съпротива

Краткосрочен план

Weak Bullish Evidence

Средносрочен план

Weak Bullish Evidence

Дългосрочен план

Bullish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Innate Pharma SA

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.
help-icon Live chat